DÄ internationalArchiveReferences
References

Review article

Radiotherapy and Hormone Treatment in Prostate Cancer

Dtsch Arztebl Int 2016; 113: 235-41. DOI: 10.3238/arztebl.2016.0235

Böhmer, D; Wirth, M; Miller, K; Budach, V; Heidenreich, A; Wiegel, T

1.Krebs in Deutschland: 10th edition. Saarbrücken: Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. und das Robert-Koch-Institut 2015.
2.Leitlinienprogramm Onkologie (eds.): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Version 3.1. 2014.
3.Konaka H, Egawa S, Saito S, et al.: Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 2012; 12: 110 CrossRef MEDLINE PubMed Central
4.Heidenreich A, Bastian PJ, Bellmunt J, et al.: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124–37 CrossRef MEDLINE
5. Allen AM, Pawlicki T, Dong L, et al.: An evidence based review of proton beam therapy: the report of ASTRO’s emerging technology committee. Radiother Oncol 2012; 103: 8–11 CrossRef MEDLINE
6.Pollack A, Walker G, Horwitz EM, et al.: Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013; 31: 3860–8 CrossRef MEDLINE PubMed Central
7.Norkus D, Karklelyte A, Engels B, et al.: A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol 2013; 8: 206.
8.Arcangeli S, Strigari L, Gomellini S, et al.: Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84: 1172–8 CrossRef CrossRef MEDLINE
9.Bekelman JE, Mitra N, Efstathiou J, et al.: Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81: e325–e334 CrossRef MEDLINE PubMed Central
10.Michalski JM, Yan Y, Watkins-Bruner D, et al.: Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 2013; 87: 932–8 CrossRef MEDLINE PubMed Central
11.Lattanzi J, McNeeley S, Pinover W, et al.: A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. Int J Radiat Oncol Biol Phys 1999; 43: 719–25 CrossRef
12.Poulsen PR, Fokdal L, Petersen J, Hoyer M: Accuracy of image-guided radiotherapy of prostate cancer based on the BeamCath urethral catheter technique. Radiother Oncol 2007; 83: 25–30 CrossRef MEDLINE
13.Sterzing F, Engenhart-Cabillic R, Flentje M, Debus J: Image-guided radiotherapy: a new dimension in radiation oncology. Dtsch Arztebl Int 2011; 108: 274–80 VOLLTEXT
14.Lawton CA, DeSilvio M, Roach M 3rd, et al.: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94–13, with emphasis on unexpected hormone/ radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646–55 CrossRef MEDLINE PubMed Central
15.Roach M 3rd, Marquez C, Yuo HS, et al.: Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28: 33–7 CrossRef
16.Nguyen PL, Chen MH, Hoffman KE, Katz MS, D’Amico AV: Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys 2009; 74: 104–9 CrossRef MEDLINE
17.Yu JB, Makarov DV, Gross C: A new formula for prostate cancer lymph node risk. Int J Radiat Oncol Biol Phys 2011; 80: 69–75 CrossRef MEDLINE
18.Abdollah F, Cozzarini C, Sun M, et al.: Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. Radiother Oncol 2013; 109: 211–6 CrossRef MEDLINE
19.Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P: Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 2012; 62: 213–9 CrossRef MEDLINE
20.Warde P, Mason M, Ding K, et al.: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104–11 CrossRef
21.Widmark A, Klepp O, Solberg A, et al.: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301–8 CrossRef
22.Kucway R, Vicini F, Huang R, Stromberg J, Gonzalez J, Martinez A: Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002; 167: 2443–7 CrossRef
23.Zelefsky MJ, Leibel SA, Burman CM, et al.: Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29: 755–61 CrossRef
24.Denham JW, Steigler A, Lamb DS, et al.: Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12: 451–9 CrossRef
25.Lamb DS, Denham JW, Joseph D, et al.: A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial. Int J Radiat Oncol Biol Phys 2011; 79: 385–91 CrossRef MEDLINE
26.Crook J, Ludgate C, Malone S, et al.: Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73: 327–33 CrossRef MEDLINE
27.Alexander A, Crook J, Jones S, et al.: Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 2010; 76: 23–30 CrossRef MEDLINE
28.Pisansky TM, Hunt D, Gomella LG, et al.: Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol 2015; 33: 332–9 CrossRef MEDLINE PubMed Central
29.Denham JW, Steigler A, Joseph D, et al.: Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiother Oncol 2015; 115: 301–7 CrossRef MEDLINE
30.Jones CU, Hunt D, McGowan DG, et al.: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107–18 CrossRef MEDLINE
31.D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW: Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289–95 CrossRef
32.Fizazi K, Faivre L, Lesaunier F, et al.: Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015; 16: 787–94 CrossRef
33.Denham JW, Joseph D, Lamb DS, et al.: Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol 2014; 15: 1076–89 CrossRef
34.Siglin J, Kubicek GJ, Leiby B, Valicenti RK: Time of decline in sexual function after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 76: 31–5 CrossRef MEDLINE
35.Budäus L, Bolla M, Bossi A, et al.: Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 2012; 61: 112–27 CrossRef MEDLINE
36.Clarke RE, Tenorio LM, Hussey JR, et al.: Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys 2008; 72: 134–43 CrossRef MEDLINE
37.Huang J, Kestin LL, Ye H, Wallace M, Martinez AA, Vicini FA: Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiother Oncol 2011; 98: 81–6 CrossRef MEDLINE
38.Bolla M, de Reijke TM, van Tienhoven G, et al.: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516–27 CrossRefMEDLINE
39.Nguyen PL, Chen MH, Beckman JA, et al.: Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 2012; 82: 1411–6 CrossRef MEDLINE
40.Kohutek ZA, Steinberger E, Pei X, et al.: Long-term impact of androgen-deprivation therapy on cardiovascular morbidity after radiotherapy for clinically localized prostate cancer. Urology 2016; 87: 146–52 CrossRef MEDLINE
e1.D’Amico AV, Whittington R, Malkowicz SB, et al.: Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17: 168–72.
e2.Kuban DA, Levy LB, Cheung MR, et al.: Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011; 79: 1310–7 CrossRef MEDLINE
e3.Kuban DA, Tucker SL, Dong L, et al.: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 67–74 CrossRef MEDLINE
e4.Al-Mamgani A, van Putten WL, Heemsbergen WD, et al.: Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 980–8 CrossRef MEDLINE
e5.Zietman AL, Bae K, Slater JD, et al.: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95–09. J Clin Oncol 2010; 28: 1106–11 CrossRef MEDLINE PubMed Central
e6.Zietman AL, DeSilvio ML, Slater JD, et al.: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294: 1233–9 CrossRef MEDLINE
e7.Beckendorf V, Guerif S, Le Prise E, et al.: 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011; 80: 1056–63 CrossRef MEDLINE
e8.Dearnaley DP, Sydes MR, Graham JD, et al.: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
Lancet Oncol 2007; 8: 475–87 CrossRef
e9.Dearnaley DP, Jovic G, Syndikus I, et al.: Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Lancet Oncol 2014; 15: 464–73 CrossRef
e10.Sharma NK, Li T, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK: Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 437–44 CrossRef MEDLINE
e11.Zelefsky MJ, Kollmeier M, Cox B, et al.: Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012.
e12.Vora SA, Wong WW, Schild SE, Ezzell GA, Halyard MY: Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1053–8 CrossRef MEDLINE
e13.Vesprini D, Catton C, Jacks L, et al.: Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2012; 83: 608–16 CrossRef MEDLINE
e14.Eade TN, Horwitz EM, Ruth K, et al.: A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys 2008; 71: 338–45 CrossRef MEDLINE PubMed Central
e15.Brundage M, Sydes MR, Parulekar WR, et al.: Impact of radio-
therapy when added to androgen-deprivation therapy for locally advanced prostate cancer: long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial. J Clin Oncol 2015; 33: 2151–7 CrossRef MEDLINE
e16.Zapatero A, Guerrero A, Maldonado X, et al.: High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 2015; 16: 320–7 CrossRef
e17.D’Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW: Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 2008; 26: 2979–83 CrossRef MEDLINE
e18.Roach M, 3rd, Bae K, Speight J, et al.: Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26: 585–91 CrossRef MEDLINE
e19.Pilepich MV, Winter K, Lawton CA, et al.: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—
long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys 2005; 61: 1285–90 CrossRef MEDLINE
e20.Horwitz EM, Bae K, Hanks GE, et al.: Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497–504 CrossRef MEDLINE
e21.Bolla M, van Tienhoven G, Warde P, et al.: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066–73 CrossRef
e22.Zhao J, Zhu S, Sun L, et al.: Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PloS one 2014; 9: e107516.
e23.Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J: Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014; 65: 565–73 CrossRef MEDLINE
e24.Nguyen PL, Je Y, Schutz FA, et al.: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306: 2359–66 CrossRef MEDLINE
e25. Efstathiou JA, Bae K, Shipley WU, et al.: Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31. J Clin Oncol 2009; 27: 92–9 CrossRef MEDLINE PubMed Central
e26.Teoh JY, Chiu PK, Chan SY, et al.: Risk of new-onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population. J Diabetes 2015; 7: 672–80 CrossRef MEDLINE
e27. Levine GN, D’Amico AV, Berger P, et al.: Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121: 833–40 CrossRef MEDLINE PubMed Central